| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.082 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.074 | 0.1 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.083 | 0.1 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | -0.076 | 0.1 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |